Orthocell Ltd (AU:OCC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Orthocell Ltd is gearing up for a significant entry into the $1.6 billion U.S. nerve repair market with its FDA 510(k) application to distribute Remplir™, a revolutionary nerve repair product. The company anticipates regulatory clearance by early 2025 and is already preparing for a commercial launch with a strong financial position and a dedicated U.S. sales team. With Remplir’s proven success in other markets, this move represents a promising growth opportunity for Orthocell.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
